{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=placebo+oral+capsules&page=23",
    "query": {
      "intervention": "placebo oral capsules",
      "page": 23
    },
    "page_size": 10
  },
  "pagination": {
    "page": 23,
    "page_size": 10,
    "total_count": 2673,
    "total_pages": 268,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=placebo+oral+capsules&page=24&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=placebo+oral+capsules&page=22&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-16T07:53:42.087Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03247530",
      "title": "Evaluation of SPN-812 (Viloxazine Extended-release Capsule) Low Dose in Children With ADHD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "ADHD"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "100mg SPN-812",
          "type": "DRUG"
        },
        {
          "name": "200mg SPN-812",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Supernus Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "11 Years",
        "sex": "ALL",
        "summary": "6 Years to 11 Years"
      },
      "enrollment_count": 477,
      "start_date": "2017-10-20",
      "completion_date": "2018-09-12",
      "has_results": true,
      "last_update_posted_date": "2021-07-02",
      "last_synced_at": "2026-10-16T07:53:42.087Z",
      "location_count": 7,
      "location_summary": "Dothan, Alabama • Hialeah, Florida • Meridian, Idaho + 4 more",
      "locations": [
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "Hialeah",
          "state": "Florida"
        },
        {
          "city": "Meridian",
          "state": "Idaho"
        },
        {
          "city": "Rochester",
          "state": "New York"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03247530"
    },
    {
      "nct_id": "NCT00754065",
      "title": "To Compare SH T00658ID Over Ortho Tri-Cyclen Lo (US/Canada)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Contraception"
      ],
      "interventions": [
        {
          "name": "Estradiol valerate, Dienogest (Natazia, Qlaira, BAY86-5027)",
          "type": "DRUG"
        },
        {
          "name": "Ortho Tri Cyclen Lo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 50 Years · Female only"
      },
      "enrollment_count": 409,
      "start_date": "2008-09-08",
      "completion_date": "2011-05-10",
      "has_results": true,
      "last_update_posted_date": "2024-11-20",
      "last_synced_at": "2026-10-16T07:53:42.087Z",
      "location_count": 34,
      "location_summary": "Independence, Arizona • Phoenix, Arizona • Encinitas, California + 29 more",
      "locations": [
        {
          "city": "Independence",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Encinitas",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00754065"
    },
    {
      "nct_id": "NCT00789464",
      "title": "Probiotics for Girls With Recurring Urinary Tract Infections",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Recurrent Urinary Tract Infection"
      ],
      "interventions": [
        {
          "name": "Lactobacillus reuteri DSM 17938",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "trimethoprim/sulfamethoxazole",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT",
        "DRUG"
      ],
      "sponsor": "Baylor College of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Months",
        "maximum_age": "17 Years",
        "sex": "FEMALE",
        "summary": "3 Months to 17 Years · Female only"
      },
      "enrollment_count": 0,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2020-08-18",
      "last_synced_at": "2026-10-16T07:53:42.087Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00789464"
    },
    {
      "nct_id": "NCT01073319",
      "title": "Rivastigmine as a Treatment for Methamphetamine Dependence",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Methamphetamine Dependence",
        "Substance Abuse",
        "Methamphetamine Abuse"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "Rivastigmine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "Baylor College of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 17,
      "start_date": "2009-07",
      "completion_date": "2010-07",
      "has_results": false,
      "last_update_posted_date": "2012-07-27",
      "last_synced_at": "2026-10-16T07:53:42.087Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01073319"
    },
    {
      "nct_id": "NCT00571701",
      "title": "Study of Celebrex (Celecoxib) in Patients With Recurrent Respiratory Papillomatosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Recurrent Respiratory Papillomatosis"
      ],
      "interventions": [
        {
          "name": "celebrex (celecoxib)",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Northwell Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "2 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2008-02",
      "completion_date": "2015-01",
      "has_results": true,
      "last_update_posted_date": "2017-05-15",
      "last_synced_at": "2026-10-16T07:53:42.087Z",
      "location_count": 7,
      "location_summary": "Birmingham, Alabama • San Francisco, California • Iowa City, Iowa + 4 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "New Hyde Park",
          "state": "New York"
        },
        {
          "city": "Sioux Falls",
          "state": "South Dakota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00571701"
    },
    {
      "nct_id": "NCT04236219",
      "title": "ALLN-346 Single Ascending Dose (SAD) Study in Healthy Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hyperuricemia"
      ],
      "interventions": [
        {
          "name": "ALLN-346",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Allena Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 24,
      "start_date": "2020-09-02",
      "completion_date": "2020-11-06",
      "has_results": false,
      "last_update_posted_date": "2021-07-23",
      "last_synced_at": "2026-10-16T07:53:42.087Z",
      "location_count": 1,
      "location_summary": "Cincinnati, Ohio",
      "locations": [
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04236219"
    },
    {
      "nct_id": "NCT01298219",
      "title": "Opioid-induced Bowel Dysfunction (OBD) Pivotal Assessment of Lubiprostone (OPAL)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Opioid-induced Bowel Dysfunction"
      ],
      "interventions": [
        {
          "name": "Lubiprostone",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sucampo Pharma Americas, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 439,
      "start_date": "2010-12",
      "completion_date": "2011-11",
      "has_results": true,
      "last_update_posted_date": "2020-02-11",
      "last_synced_at": "2026-10-16T07:53:42.087Z",
      "location_count": 115,
      "location_summary": "Athens, Alabama • Birmingham, Alabama • Foley, Alabama + 89 more",
      "locations": [
        {
          "city": "Athens",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Foley",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01298219"
    },
    {
      "nct_id": "NCT01938001",
      "title": "Rituximab Plus Lenalidomide for Patients With Relapsed / Refractory Indolent Non-Hodgkin's Lymphoma (Follicular Lymphoma and Marginal Zone Lymphoma)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Lymphoma, Non-Hodgkin"
      ],
      "interventions": [
        {
          "name": "Rituximab",
          "type": "DRUG"
        },
        {
          "name": "Lenalidomide",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Celgene",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 358,
      "start_date": "2013-11-21",
      "completion_date": "2022-01-26",
      "has_results": true,
      "last_update_posted_date": "2023-02-22",
      "last_synced_at": "2026-10-16T07:53:42.087Z",
      "location_count": 35,
      "location_summary": "Mobile, Alabama • Glendale, Arizona • Escondido, California + 31 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Escondido",
          "state": "California"
        },
        {
          "city": "Greenbrae",
          "state": "California"
        },
        {
          "city": "La Verne",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01938001"
    },
    {
      "nct_id": "NCT02156843",
      "title": "Pyridorin in Diabetic Nephropathy",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetic Nephropathy",
        "Diabetic Kidney Disease"
      ],
      "interventions": [
        {
          "name": "Pyridorin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "NephroGenex, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 328,
      "start_date": "2014-06",
      "completion_date": "2018-03",
      "has_results": false,
      "last_update_posted_date": "2016-03-09",
      "last_synced_at": "2026-10-16T07:53:42.087Z",
      "location_count": 55,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Prescott, Arizona + 47 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Prescott",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02156843"
    },
    {
      "nct_id": "NCT03640052",
      "title": "Pharmacological Activation of HMN for OSA",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Obstructive Sleep Apnea"
      ],
      "interventions": [
        {
          "name": "Placebo oral capsule",
          "type": "DRUG"
        },
        {
          "name": "LTM1201L",
          "type": "DRUG"
        },
        {
          "name": "LTM1201LN",
          "type": "DRUG"
        },
        {
          "name": "LTM1201LB",
          "type": "DRUG"
        },
        {
          "name": "LTM1201LD",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Brigham and Women's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 6,
      "start_date": "2018-10-30",
      "completion_date": "2019-12-31",
      "has_results": true,
      "last_update_posted_date": "2020-02-24",
      "last_synced_at": "2026-10-16T07:53:42.087Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03640052"
    }
  ]
}